Clinical Trials Browser

Melanoma

NCT06564623 2025-12-05

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase 1 Recruiting

25 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT03223103 2025-09-10

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Phase 1 Active not recruiting

13 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasms

NCT06195618 2025-06-25

TEBICA003 TNBC

Phase 1 Not yet recruiting

8 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01176474 2023-07-19

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Phase 1 Completed

73 enrolled

Dermatologic

Melanoma

NCT04379960 2022-09-22

CanVac

Completed

192 enrolled

The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data

NCT02721043 2021-01-11

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Phase 1 Completed

13 enrolled

Tumor-Agnostic

Neoplasms

NCT04072900 2020-04-28

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Phase 1 Unknown

30 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

Phase 2 Completed

98 enrolled 11 charts

Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

NCT03643068 2018-11-06

Phase 1A Study of the Safety of KSP/QRH Dimer

Phase 1 Completed

26 enrolled

Healthy Adults

NCT01008527 2015-09-24

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Phase 1 Completed

22 enrolled

Dermatologic

Melanoma

NCT00798629 2012-09-24

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

Phase 1 Completed

13 enrolled

Dermatologic

Melanoma

NCT00995358 2009-10-15

A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer

Phase 2 Unknown

60 enrolled

Gastrointestinal

Esophageal Neoplasms

Clinical Trials

A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

TEBICA003 TNBC

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

CanVac

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

Melanoma Vaccine With Peptides and Leuprolide

Phase 1A Study of the Safety of KSP/QRH Dimer

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer